english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the March issue of Prescrire International: polatuzumab vedotin (Polivy°) and large B-cell lymphoma

FREE DOWNLOADPolatuzumab vedotin has been granted conditional European marketing authorisation for certain patients with relapsed or refractory diffuse large B-cell lymphoma. How do Prescrire's editors rate this option?
Full text available for free download.
1 March 2021

Doing one's job

EDITORIALThe entire health system should be able to count on pharmaceutical companies to do their job, no more, no less. When the roles within the system become blurred, the quality of health care and patients' freedom to choose according to their needs both suffer.
1 March 2021

Annual Prescrire Awards for 2020: 3 winning drugs, including the first "Pilule d'Or" in 6 years

Prescrire AwardsThe independent French medical journal Prescrire has published its annual Awards for drugs, drug packaging and information provided by drug companies in 2020. Two drugs made the "Honours List", and Prescrire's "Pilule d'Or" (Golden Pill) was awarded for the first time in 6 years.
1 March 2021

Atopic eczema: avoid tacrolimus (Protopic° and other brands) and pimecrolimus (Elidel°)

In addition to avoiding factors causing skin irritation, the first-line treatment of atopic eczema is still based on application of an emollient and a topical corticosteroid.
1 March 2021

Dry eye: sometimes drug-induced

The daily lives of many patients are affected by discomfort and visual disturbances, or even ocular lesions, associated with dry eye syndrome. Drugs are sometimes to blame.
1 March 2021

Comparative trials: an ethical issue

Mounting evidence that hydroxychloroquine (Plaquenil°) lacks the efficacy expected in covid-19 has shown the medical and ethical risks of using drugs on the basis of inadequate evidence.
1 March 2021

Prescrire’s response to the European Commission consultation on a "European Health Emergency Preparedness and Response Authority"

23 February 2021

Covid-19 and ivermectin: many trials, few results, no proven efficacy

 NEWS UPDATE  The antiparasitic drug ivermectin has been shown to have in vitro activity against Sars-CoV-2. What are the main results available in early February 2021 from comparative clinical trials of ivermectin in the treatment and prevention of covid-19?
13 February 2021

The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy

 NEWS UPDATE  Unlike the first two covid-19 vaccines authorised in Europe, which are messenger RNA vaccines, the covid19 vaccine ChAdOx1 nCoV-19, developed by the University of Oxford and the pharmaceutical company AstraZeneca, is a "viral vector" vaccine. What are the main data available in late January 2021 from the clinical trials of this new vaccine?
29 January 2021

Prescrire publishes its annual update of drugs to avoid, in the name of better patient care

  DRUGS TO AVOID - 2021 UPDATE  For the ninth consecutive year, independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients
1 February 2021

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90